Immunovant 将来の成長
Future 基準チェック /26
Immunovant利益と収益がそれぞれ年間8.3%と75.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-175.9% 11.2%なると予測されています。
主要情報
8.3%
収益成長率
11.2%
EPS成長率
| Biotechs 収益成長 | 28.3% |
| 収益成長率 | 75.5% |
| 将来の株主資本利益率 | -175.9% |
| アナリストカバレッジ | Good |
| 最終更新日 | 20 Nov 2024 |
今後の成長に関する最新情報
Recent updates
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Oct 16
Immunovant: Switching Lead Candidates Increases Risk
Oct 14We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Jul 18Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive
Jun 27We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Apr 19Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Apr 04Immunovant: An Intriguing And Developing Story
Jan 25Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate
Jan 12We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Sep 28Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Jun 14Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Mar 08We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Nov 06Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset
Oct 17Immunovant stock down on raising $75M though equity capital
Oct 04We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Aug 06Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Apr 06We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Jun 20Immunovant EPS beats by $0.04
Jun 01argenx rise even as Immunovant pauses the trial for anti-FcRn therapy
Feb 03Immunovant slips 7% on voluntary hold of IMVT-1401 dosing
Feb 02Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management
Jan 14Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?
Dec 30Immunovant (IMVT) Investor Presentation - Slideshow
Nov 16業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 3/31/2027 | 52 | -547 | -401 | -350 | 11 |
| 3/31/2026 | 20 | -494 | -441 | -429 | 13 |
| 3/31/2025 | N/A | -425 | -356 | -348 | 13 |
| 9/30/2024 | N/A | -323 | -272 | -272 | N/A |
| 6/30/2024 | N/A | -273 | -244 | -243 | N/A |
| 3/31/2024 | N/A | -259 | -215 | -214 | N/A |
| 12/31/2023 | N/A | -243 | -211 | -210 | N/A |
| 9/30/2023 | N/A | -255 | -210 | -210 | N/A |
| 6/30/2023 | N/A | -245 | -170 | -170 | N/A |
| 3/31/2023 | N/A | -211 | -188 | -188 | N/A |
| 12/31/2022 | N/A | -199 | -166 | -165 | N/A |
| 9/30/2022 | N/A | -177 | -151 | -151 | N/A |
| 6/30/2022 | N/A | -167 | -151 | -151 | N/A |
| 3/31/2022 | N/A | -157 | -106 | -106 | N/A |
| 12/31/2021 | N/A | -138 | -96 | -96 | N/A |
| 9/30/2021 | N/A | -128 | -87 | -87 | N/A |
| 6/30/2021 | N/A | -111 | -91 | -91 | N/A |
| 3/31/2021 | N/A | -107 | -84 | -83 | N/A |
| 12/31/2020 | N/A | -100 | -84 | -84 | N/A |
| 9/30/2020 | N/A | -79 | -66 | -65 | N/A |
| 6/30/2020 | N/A | -73 | -59 | -59 | N/A |
| 3/31/2020 | N/A | -66 | -53 | -53 | N/A |
| 12/31/2019 | N/A | -55 | -43 | -43 | N/A |
| 9/30/2019 | N/A | -52 | -46 | -46 | N/A |
| 6/30/2019 | N/A | -44 | -32 | -32 | N/A |
| 3/31/2019 | N/A | -29 | -29 | -29 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: IMVT今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: IMVT今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: IMVT今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: IMVTの収益 ( 75.5% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。
高い収益成長: IMVTの収益 ( 75.5% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: IMVT 3 年以内に赤字になると予測されています。